Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.
about
Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learningThree-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugsSeven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Review of the acetylcholinesterase inhibitor galanthamine.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Structural answers and persistent questions about how nicotinic receptors work.Cholinergic modulation of the cortical neuronal network.Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats.The effects of postnatal alcohol exposure and galantamine on the context pre-exposure facilitation effect and acetylcholine efflux using in vivo microdialysis.Sustaining high acetylcholine levels in the frontal cortex, but not retrosplenial cortex, recovers spatial memory performance in a rodent model of diencephalic amnesiaNicotinic receptors in neurodegeneration.Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration.In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity.Photoaffinity labeling of nicotinic receptors: diversity of drug binding sites!The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory.Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined.Desensitization of neuronal nicotinic receptors of human neuroblastoma SH-SY5Y cells during short or long exposure to nicotine.Activation of heteroliganded mouse muscle nicotinic receptors.Histochemical study of acute and chronic intraperitoneal nicotine effects on several glycolytic and Krebs cycle dehydrogenase activities in the frontoparietal cortex and subcortical nuclei of the rat brain.Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones.Awake bruxism in a patient with Alzheimer's dementia.Chronic nicotine administration increases NGF-like immunoreactivity in frontoparietal cerebral cortex.Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice.Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.Simvastatin Enhances Spatial Memory and Long-Term Potentiation in Hippocampal CA1 via Upregulation of α7 Nicotinic Acetylcholine Receptor.Time Course, Behavioral Safety, and Protective Efficacy of Centrally Active Reversible Acetylcholinesterase Inhibitors in Cynomolgus Macaques.Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.Allosteric agonist modulators.Chromatographic Tandem Mass Spectrometric Detection of Physostigmine and its Major Metabolites in Rat Urine
P2860
Q24609985-0A45C95E-53BF-4608-823C-9E6B65BED881Q27628948-59E99CF4-DAF6-4EDB-9E5C-A13034785E08Q33890786-9583C12E-965E-4606-B948-6DCBBBBB83CDQ34075135-BB02B86E-8F6C-4D18-A3EA-6E4E4DC23868Q34327769-CEAC2709-2187-4BD7-A07A-0C143C63D9A1Q34782188-8A708175-345B-4AB9-BF87-CC4AE88ABFEDQ35104959-9D674951-11E8-4D2B-A393-973ABCCEE420Q35182101-852A09B9-3E47-4BE9-8C2C-3DEE26F9D120Q35534146-E7354D68-B1A0-4434-98BD-980AB222B391Q35554418-DD3DDDE9-FD5E-4994-86F5-52857B6EACA4Q35859851-C152CE0E-DD73-4F40-8529-1D064A0D9D27Q36828916-D8718B4E-A819-423B-A46F-8FD83750D5B4Q37092481-3DE21A0E-D5FE-42CD-A057-C652B4C34C74Q37230901-C7F725D0-9512-4B9C-86E4-F241B55E9BDCQ37894710-B2BB2CB0-E10F-4C07-B9C7-A835BB4EBDA9Q38155454-D80CD785-C0F8-47C7-9C6B-74ECD7271210Q39016614-34D307F9-53A8-4CAF-B3E1-132AA3086CCBQ39223215-CE622000-68E2-41E5-9E5D-17B080CECFAEQ40360827-9D6E118F-E35E-4C91-8908-F34964F4BE7EQ40457011-F77806AE-20BE-41FF-845D-365614C2363BQ42505578-A78E6E16-7446-4CDF-BAED-BDCE6C06C8E5Q43263076-0C7BD718-6D93-4D10-B052-4F1747E2CCAAQ43417825-6A5E8430-D93B-4A6C-A4A9-DED434C5A930Q44556491-17688853-294B-447A-9D8E-E2D7F1F6BA28Q48395191-FBDE83BA-D0B8-4D5C-839D-AEEABA23D715Q48565611-E77CAD41-2089-40EF-9D7A-3D2C3E4B02CCQ50576727-20B7113E-C9E2-412D-A99F-EF5FE3D63012Q51036690-4E05D2B5-09E4-4145-8F19-63B004434EF3Q53313228-CDAC82FD-B8F8-4A41-BE7F-C932750AA857Q53561771-E57A36D3-7987-4889-967A-827B7ACCE0A6Q58129822-FFB22B20-C7B8-41F2-956F-86A145502C06
P2860
Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@ast
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@en
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@nl
type
label
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@ast
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@en
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@nl
prefLabel
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@ast
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@en
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@nl
P2093
P1476
Allosterically potentiating li ...... ategy for Alzheimer's disease.
@en
P2093
Albuquerque EX
Maelicke A
Samochocki M
Schrattenholz A
P304
P356
10.1016/S0166-4328(00)00214-X
P407
P577
2000-08-01T00:00:00Z